BPMC - ブル―プリント・メディシンズ （Blueprint Medicines Corporation） ブル―プリント・メディシンズBPMCのチャート
BPMCの企業情報
| symbol | BPMC |
|---|---|
| 会社名 | Blueprint Medicines Corp （ブル―プリント・メディシンズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ブループリント・メディシンズ（Blueprint Medicines Corporation）はバイオ医薬品会社である。同社は、異常なキナーゼ活性化によって遺伝的に定義された疾患患者を中心とする。同社は適切な治療オプションがない患者に臨床的応答を提供する薬剤候補を作ることに焦点を当てる。同社は癌と遺伝病における小分子薬物パイプラインを開発した。薬剤候補のBLU-285は、エクソン17突然変異を含むKIT、及びD842V突然変異を含むPDGFRaを対象とする。これらの突然変異は、胃腸間質腫瘍（GIST）および全身性肥満細胞症（SM）を含む癌および増殖性障害の原因である受容体チロシンキナーゼを活性化する。薬物候補BLU-554は、肝細胞癌の一般的なタイプである肝細胞癌（HCC）を有する患者の定義されたサブセットにおいて活性化されるキナーゼであるFGFR4を対象とする。同社は突然変異または転座によって活性化された受容体チロシンキナーゼであるRETを対象とする薬剤候補のBLU-667の開発に従事している。 ブル―プリント・メディシンズは米国のバイオ医薬品会社。がん分子標的治療薬やキナ―ゼ阻害剤の開発を行う。異常なキナ―ゼ活性化によって発症するゲノム的に定義された疾患向け治療薬の開発に従事する。同社の「BLU-285」は、全身性肥満細胞症で胃腸管の消化管間質腫瘍や骨髄増殖性障害を有する患者向けに開発された。本社はマサチュ―セッツ州ケンブリッジ。 blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development |
| 本社所在地 | 45 Sidney Street Suite 200 Cambridge MA 02139 USA |
| 代表者氏名 | Daniel S. Lynch ダニエルS.リンチ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-374-7580 |
| 設立年月日 | 39722 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 149人 |
| url | www.blueprintmedicines.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bpmc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -174.38100 |
| 終値（lastsale） | 69.43 |
| 時価総額（marketcap） | 3047125232.76 |
| 時価総額 | 時価総額（百万ドル） 311.137 |
| 売上高 | 売上高（百万ドル） 52.08900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2398.373 |
| 当期純利益 | 当期純利益（百万ドル） -170.32700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Blueprint Medicines Corp revenues increased from $11.7M to $42.4M. Net loss increased 36% to $83.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other Research and development increase of 71% to $101.2M (expense) Other General and administrative increase of 63% to $16.2M (expense). |
BPMCのテクニカル分析
BPMCのニュース
Q3 2023 Earnings Estimate for Blueprint Medicines Co. Issued By Wedbush (NASDAQ:BPMC) 2023/05/29 05:38:42 The AM Reporter
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) – Equities researchers at Wedbush boosted their Q3 2023 EPS estimates for shares of Blueprint Medicines in a report issued on Wednesday, May 24th. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($2.39) per share for the quarter, up from their prior estimate of […]
Blueprint Medicines Co. Expected to Post Q2 2023 Earnings of ($2.45) Per Share (NASDAQ:BPMC) 2023/05/26 05:34:47 The AM Reporter
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) – Equities research analysts at Wedbush boosted their Q2 2023 earnings per share (EPS) estimates for Blueprint Medicines in a report released on Tuesday, May 23rd. Wedbush analyst D. Nierengarten now expects that the biotechnology company will post earnings per share of ($2.45) for the quarter, up from […]
Citi maintains Blueprint Medicines Corp at ''sell'' with a price target of $46.00 2023/05/24 07:47:41 Investing.com
https://www.investing.com/news/pro/blueprint-medicines-corp-receives-investment-bank-analyst-rating-update-3089361
Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit''s Future 2023/05/23 19:03:31 Benzinga
Shares of Blueprint Medicines Corporation (NASDAQ: BPMC ) after it received FDA approval for its Ayvakit (avapritinib) as the first, only treatment for Latest … Full story available on Benzinga.com
FDA OKs Blueprint Medicines'' Blood Disorder Drug As First Treatment For SM Patients 2023/05/23 17:55:22 Benzinga
The U.S. Food and Drug Administration (FDA) approved Blueprint Medicines Corporation''s (NASDAQ: BPMC ) Ayvakit (avapritinib) for the treatment of adults with indolent systemic mastocytosis (ISM) . Systemic mastocytosis (SM) is a rare hematologic disorder. ISM represents the vast majority of SM cases, and Ayvakit is now available for adults with ISM at the recommended dose of 25 mg once daily. Ayvakit was designed to potently and selectively inhibit KIT D816V, the primary underlying driver of the disease. Ayvakit … Full story available on Benzinga.com
Blueprint Medicines PT Lowered to $115 at Raymond James 2022/08/02 16:51:02 Investing.com
https://www.investing.com/news/pro/blueprint-medicines-pt-lowered-to-115-at-raymond-james-432SI-2860818
Blueprint Medicines Corporation''s (BPMC) CEO Kate Haviland on Q2 2022 Results - Earnings Call Transcript 2022/08/02 15:31:04 Seeking Alpha
Blueprint Medicines Corporation (NASDAQ:NASDAQ:BPMC) Q2 2022 Earnings Conference Call August 2, 2022 8:00 A.M.
BPMC stock climbs ahead of key data readout despite 2Q miss (NASDAQ:BPMC) 2022/08/02 14:52:27 Seeking Alpha
Shares of oncology focused Blueprint Medicines (BPMC) surged ~13% in the morning hours Tuesday despite lower-than-expected financials for 2Q 2022 as management outlined plans to report…
Blueprint Medicines: Q2 Earnings Insights 2022/08/02 11:39:56 Benzinga
Blueprint Medicines (NASDAQ: BPMC ) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Blueprint Medicines missed estimated earnings by 20.18%, reporting an EPS of $-2.68 versus … Full story available on Benzinga.com